Ovulation disorders: Part II. Anovulation associated with normal estrogen.

Area of Science:

• Reproductive Endocrinology
• Gynecology
• Infertility Management

Background:

• Anovulatory states, characterized by the absence of ovulation, are a common cause of infertility in women.
• Normal estrogen levels in the presence of anovulation suggest specific underlying endocrine or metabolic dysfunctions.
• Conditions discussed include polycystic ovarian syndrome (PCOS), hyperprolactinemia, and congenital adrenal hyperplasia (CAH).

Discussion:

• Treatment options for anovulation include ovulation induction agents like clomiphene citrate and gonadotropins.
• Clomiphene citrate and gonadotropins demonstrate comparable efficacy in the initial cycles, though clomiphene may impact cervical mucus.
• Adjunctive therapies such as glucocorticoids and insulin sensitizers can improve outcomes, particularly in PCOS.
• Management of complications like luteinized unruptured follicle (LUF) syndrome, premature luteinization, and luteal phase deficiency is crucial.

Key Insights:

• Clomiphene citrate and gonadotropins are effective first-line treatments for ovulation induction.
• Combination therapy with glucocorticoids and insulin-sensitizing agents offers benefits for specific anovulatory disorders.
• Vaginal progesterone is effective for correcting luteal phase defects.
• Human chorionic gonadotropin (hCG), follicle-stimulating hormone (FSH), and GnRH analogs are essential for managing LUF syndrome and premature luteinization.

Outlook:

• Further research into personalized treatment protocols for anovulatory disorders is warranted.
• Optimizing the use of existing therapies can improve pregnancy rates and reduce treatment-related complications.
• Understanding the interplay between different hormonal pathways is key to advancing anovulation management.